Anthem Biosciences Share Price : Shares of Anthem Biosciences Ltd. made a robust debut on the Indian stock exchanges on July 21, 2025, listing at ₹723.05 on NSE and ₹723.10 on BSE, marking a 26.85% premium over the IPO issue price of ₹5702. The Bengaluru-based CRDMO (Contract Research, Development, and Manufacturing Organisation) raised ₹3,395 crore through a fully offer-for-sale (OFS) IPO, which was subscribed 67.42 times, with QIBs leading the charge at 192.80 times.
Anthem Biosciences Share Price
- Issue Price Band: ₹540–₹570
- Listing Price: ₹723.05 (NSE), ₹723.10 (BSE)
- Grey Market Premium (GMP): Estimated at ₹179, suggesting a 31% listing gain
- Actual Listing Gain: ~27%
- Market Cap Post Listing: ₹40,610 crore
Company Overview
Founded in 2006, Anthem Biosciences is a full-service CRDMO offering end-to-end drug development and manufacturing solutions. It serves over 425 global clients across 44 countries, with a portfolio that includes fermentation-based APIs, probiotics, and enzymes4. The company reported a 30% YoY revenue growth to ₹1,844 crore in FY25, with net profit rising 23% to ₹451 crore.
Buy, Sell or Hold?
Market analysts suggest a “Hold” strategy for investors who were allotted shares, citing:
- Strong financials and margins
- High demand across investor categories
- Leadership in the CRDMO space
- Long-term growth potential in biotech and pharma outsourcing5
However, for new investors, experts advise caution due to:
- Steep valuations post-listing
- No fresh issue—proceeds go to selling shareholders
- Listing below GMP expectations, indicating limited short-term upside3
If you were allotted shares in the IPO, holding for the medium to long term could be rewarding given Anthem’s strong fundamentals and global footprint. For fresh entries, consider waiting for price stabilization or dips before investing.
